Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma

Dana Lynn T. Koomoa, Tamas Borsics, David J. Feith, Craig C. Coleman, Christopher J. Wallick, Ivonne Gamper, Anthony E. Pegg, André S. Bachmann

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

S-adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme of polyamine (PA) biosynthesis, and both AdoMetDC and PA levels are often up-regulated in cancer cells. The second-generation inhibitor SAM486A inhibits AdoMetDC enzyme activity and has been evaluated in phase II clinical cancer trials. However, little is known about the mechanism of action and potential use of this therapeutic drug in the treatment of the pediatric cancer neuroblastoma (NB). Here, we show that p53 wild-type NB cells are highly sensitive to SAM486A treatment. Most notably, SAM486A treatment resulted in the rapid accumulation of proapoptotic proteins p53 and Mdm2. Concomitant with the increase of proteins at endogenous levels, the in vivo phosphorylation of p53 at residues Ser 46/Ser392 and Mdm2 at residue Ser166 was observed. Moreover, the antiapoptotic protein Akt/protein kinase B was down-regulated and also dephosphorylated at residue Ser473 in a dose- and time-dependent manner and NB cells entered apoptotic cell death. The results presented in this study highlight the importance of PA homeostasis and provide a direct link between PA metabolism and apoptotic cell signaling pathways in p53 wildtype NB cells. PA inhibitors such as SAM486A may be effective alternative agents for the treatment of NBs with or without MYCN amplification.

Original languageEnglish (US)
Pages (from-to)2067-2075
Number of pages9
JournalMolecular cancer therapeutics
Volume8
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

4-amidinoindan-1-one 2'-amidinohydrazone
Proto-Oncogene Proteins c-mdm2
Adenosylmethionine Decarboxylase
Proto-Oncogene Proteins c-akt
Polyamines
Neuroblastoma
Apoptosis
Neoplasms
Phase II Clinical Trials
Therapeutic Uses
Enzymes
Action Potentials
Proteins
Homeostasis
Cell Death
Phosphorylation
Pediatrics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Koomoa, Dana Lynn T. ; Borsics, Tamas ; Feith, David J. ; Coleman, Craig C. ; Wallick, Christopher J. ; Gamper, Ivonne ; Pegg, Anthony E. ; Bachmann, André S. / Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma. In: Molecular cancer therapeutics. 2009 ; Vol. 8, No. 7. pp. 2067-2075.
@article{792c633a19d84a83b170b499284368b2,
title = "Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma",
abstract = "S-adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme of polyamine (PA) biosynthesis, and both AdoMetDC and PA levels are often up-regulated in cancer cells. The second-generation inhibitor SAM486A inhibits AdoMetDC enzyme activity and has been evaluated in phase II clinical cancer trials. However, little is known about the mechanism of action and potential use of this therapeutic drug in the treatment of the pediatric cancer neuroblastoma (NB). Here, we show that p53 wild-type NB cells are highly sensitive to SAM486A treatment. Most notably, SAM486A treatment resulted in the rapid accumulation of proapoptotic proteins p53 and Mdm2. Concomitant with the increase of proteins at endogenous levels, the in vivo phosphorylation of p53 at residues Ser 46/Ser392 and Mdm2 at residue Ser166 was observed. Moreover, the antiapoptotic protein Akt/protein kinase B was down-regulated and also dephosphorylated at residue Ser473 in a dose- and time-dependent manner and NB cells entered apoptotic cell death. The results presented in this study highlight the importance of PA homeostasis and provide a direct link between PA metabolism and apoptotic cell signaling pathways in p53 wildtype NB cells. PA inhibitors such as SAM486A may be effective alternative agents for the treatment of NBs with or without MYCN amplification.",
author = "Koomoa, {Dana Lynn T.} and Tamas Borsics and Feith, {David J.} and Coleman, {Craig C.} and Wallick, {Christopher J.} and Ivonne Gamper and Pegg, {Anthony E.} and Bachmann, {Andr{\'e} S.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1158/1535-7163.MCT-08-1217",
language = "English (US)",
volume = "8",
pages = "2067--2075",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma. / Koomoa, Dana Lynn T.; Borsics, Tamas; Feith, David J.; Coleman, Craig C.; Wallick, Christopher J.; Gamper, Ivonne; Pegg, Anthony E.; Bachmann, André S.

In: Molecular cancer therapeutics, Vol. 8, No. 7, 01.07.2009, p. 2067-2075.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma

AU - Koomoa, Dana Lynn T.

AU - Borsics, Tamas

AU - Feith, David J.

AU - Coleman, Craig C.

AU - Wallick, Christopher J.

AU - Gamper, Ivonne

AU - Pegg, Anthony E.

AU - Bachmann, André S.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - S-adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme of polyamine (PA) biosynthesis, and both AdoMetDC and PA levels are often up-regulated in cancer cells. The second-generation inhibitor SAM486A inhibits AdoMetDC enzyme activity and has been evaluated in phase II clinical cancer trials. However, little is known about the mechanism of action and potential use of this therapeutic drug in the treatment of the pediatric cancer neuroblastoma (NB). Here, we show that p53 wild-type NB cells are highly sensitive to SAM486A treatment. Most notably, SAM486A treatment resulted in the rapid accumulation of proapoptotic proteins p53 and Mdm2. Concomitant with the increase of proteins at endogenous levels, the in vivo phosphorylation of p53 at residues Ser 46/Ser392 and Mdm2 at residue Ser166 was observed. Moreover, the antiapoptotic protein Akt/protein kinase B was down-regulated and also dephosphorylated at residue Ser473 in a dose- and time-dependent manner and NB cells entered apoptotic cell death. The results presented in this study highlight the importance of PA homeostasis and provide a direct link between PA metabolism and apoptotic cell signaling pathways in p53 wildtype NB cells. PA inhibitors such as SAM486A may be effective alternative agents for the treatment of NBs with or without MYCN amplification.

AB - S-adenosylmethionine decarboxylase (AdoMetDC) is an essential enzyme of polyamine (PA) biosynthesis, and both AdoMetDC and PA levels are often up-regulated in cancer cells. The second-generation inhibitor SAM486A inhibits AdoMetDC enzyme activity and has been evaluated in phase II clinical cancer trials. However, little is known about the mechanism of action and potential use of this therapeutic drug in the treatment of the pediatric cancer neuroblastoma (NB). Here, we show that p53 wild-type NB cells are highly sensitive to SAM486A treatment. Most notably, SAM486A treatment resulted in the rapid accumulation of proapoptotic proteins p53 and Mdm2. Concomitant with the increase of proteins at endogenous levels, the in vivo phosphorylation of p53 at residues Ser 46/Ser392 and Mdm2 at residue Ser166 was observed. Moreover, the antiapoptotic protein Akt/protein kinase B was down-regulated and also dephosphorylated at residue Ser473 in a dose- and time-dependent manner and NB cells entered apoptotic cell death. The results presented in this study highlight the importance of PA homeostasis and provide a direct link between PA metabolism and apoptotic cell signaling pathways in p53 wildtype NB cells. PA inhibitors such as SAM486A may be effective alternative agents for the treatment of NBs with or without MYCN amplification.

UR - http://www.scopus.com/inward/record.url?scp=67651183766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651183766&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-1217

DO - 10.1158/1535-7163.MCT-08-1217

M3 - Article

C2 - 19584241

AN - SCOPUS:67651183766

VL - 8

SP - 2067

EP - 2075

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -